Published: 2021-09-28

Compassionate use of convalescent plasma for the management of severe pneumonia in critically ill COVID-19 patients-a single center experience, Kerala, India

Mobin Paul, Priyanka C. G., Sophy M. P., Latha Abraham, Rajesh Venkitakrishnan, Renji Jos, Jaicob Varghese


We assessed treatment effectiveness with convalescent plasma in critically ill COVID-19 pneumonia patients and their association with reduction in C reactive protein level as a sensitive inflammatory marker to the ongoing cytokine storm. Retrospective cohort study based on the detailed electronic medical chart review. The primary outcome was a clinical improvement on day 14, defined as the reduction in cytokine storm as demonstrated by a drop in acute phase reactant C reactive protein; de-escalation from the prior mode of oxygen delivery or not on mechanical ventilation in critically ill COVID-19 patients. C reactive protein was measured by using immunoturbidimetry. IgG antibody against spike protein S1 was measured by chemiluminescent immunoassay. Of 14 patients, all had severe COVID-19 pneumonia [category C], and 9 (64%) were mechanically ventilated soon after the admission into the medical intensive care unit. De-escalation of the oxygenation strategy mode was noted in 11 (79%) patients after convalescent plasma infusion. All patients showed a significant drop in C reactive protein when compared to pre-infusion and post-infusion day 5.  Early compassionate use of convalescent plasma with higher titters of IgG antibodies against S1may positively benefit the overall outcome in critically ill COVID-19 patients with severe pneumonia.


Convalescent plasma therapy, Severe COVID-19, C reactive protein

Full Text:



WHO Pandemia WHO Director-General’s opening remarks at the media briefing on COVID-19 2020. Available at: Accessed 25 December 2020.

COVID-19 Data Repository by Center for Systems Science and Engineering (CSSE) 2021.Available at Johns Hopkins University. Available at: Accessed 10 February 2021.

Montelongo-Jauregui D, Vila T, Sultan AS, Jabra-Rizk MA. Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease. PLoS Pathogens. 2020;16(8):e1008735.

Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin microbiol reviews. 2000;13(4):602-14.

Liao H. Current status and practical considerations in the development of convalescent plasma as a treatment for COVID‐19. ISBT Sci Series. 2020;15(4):403-14.

Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. 2020;8:475-81.

Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-8.

Liu XH, Lu SH, Chen J. Clinical characteristics of foreign- imported COVID-19 cases in Shanghai, China. Emerg Microbes Infect. 2020;9:1230-32.

Sharifpour M, Rangaraju S, Liu M, Alabyad D, Nahab FB, Creel-Bulos CM et al. COVID-19 Quality and Clinical Research Collaborative. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One. 2020;15(11):e0242400.

Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. Am j trop med hygiene. 2020;103(2):561.

Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clinica chimica acta. 2020;509:91-4.

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J med virol. 2020;92(9):1475-83.

COVID-19 Convalescent plasma, Letter of Authorization, US FDA (EUA 26382). 2020.

Clinical memorandum- COVID-19 Convalescent plasma, USFDA (EUA 26382). 2020.

Convalescent plasma- Letter of authorisation. 2.4.21 Final version for concurrence, USFDA .2021.

Convalescent plasma-Corona disease 2019 (COVID-19) treatment guidelines. Available at: Accessed 7 March 2021.

Shen C. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582-9.

Xingsheng Hu. Effectiveness of convalescent plasma therapy for COVID-19 patients in Hunan, China: Dose-Response. Int J. 2020:1-12.

Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. E-Clin Med. 2020;26:100525.

Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest. Translational med communications. 2020;5(1):1-6.

Liu ST, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature med. 2020;26(11):1708-13.

Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am j pathol. 2020;190(11):2290-303.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings National Academy Sci. 2020;117(17):9490-6.